VivoSeq
Neurology

Multiple Sclerosis

461

Pipeline Programs↗

132

Active Trials↗

125

Companies Involved↗

Multiple Sclerosis is a highly competitive landscape with 461 programs across 125 companies. The most active players are AstraZeneca, Kyverna Therapeutics, Elan Pharmaceuticals. 68 therapies are approved with 98 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

94/100

Pipeline Velocity

68/100

Mech. Concentration

6/100

Completion Rate

78/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

2 programs

Phase 1K

Kyverna Therapeutics

2 programs

Phase 1E

Elan Pharmaceuticals

1 program

Phase 1I

Indapta Therapeutics, INC.

1 program

Phase 1J

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

1 program

Phase 1I

ImStem Biotechnology

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical56

Natalizumab

Biogen

Alemtuzumab

Genzyme, a Sanofi Company

Interferon Beta-1a

EMD Serono

Interferon Beta-1b

Bayer

Incobotulinumtoxina

Merz Pharmaceuticals GmbH

Phase 171

Fludarabine Phosphate

Sanofi

Ferumoxytol

Azurity Pharmaceuticals

Lithium Carbonate

Solvay Pharmaceuticals

Palifermin

Swedish Orphan Biovitrum

Bryostatin 1

National Cancer Institute (NCI)

Phase 2168

Memantine

AbbVie

Curcumin

Merck & Co.

Belimumab

Glaxo Dba Glaxosmithkline

Secukinumab

Novartis

Metformin Hydrochloride

Boehringer Ingelheim

Phase 398

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Dextromethorphan

Pfizer

Peginterferon Alfa-2b

Merck & Co.

Baclofen

Novartis

Duloxetine Hydrochloride

Eli Lilly

Approved68

Ozanimod

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Ocrelizumab

Roche

Topiramate

Wim Janssens

Leflunomide

Sanofi

Dimethyl Fumarate

Biogen

Analysis

Modality Breakdown

86%

Small molecule

428 of 498 classified programs — the dominant modality here.

14%ALL OTHERSCell therapy245%Monoclonal antibody224%Vaccine143%Protein / enzyme71%Peptide1<1%RNA therapy1<1%Other1<1%

Small molecule leads; the ring shows all 498 classified programs, each share of the total. Modality classified for 99% of 561 pipeline programs.

Analysis

Trial Status

769

clinical trials

Completed451 · 59%
Terminated92 · 12%
Recruiting67 · 9%
Unknown status59 · 8%
Active, not recruiting40 · 5%
Withdrawn30 · 4%
Other30 · 4%

Clinical Trials

Trial Activity

769 trials

Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis
Recruiting·AAmsterdam UMC, location VUmc·Phase 3·NCT05338450·80 enrolled
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT06408259·194 enrolled
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Recruiting·Moderna logoModerna·Phase 2·NCT06735248·180 enrolled
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Recruiting·JJohns Hopkins University·Phase 2·NCT06170970·46 enrolled
MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis
Recruiting·—·Phase 2·NCT06592352·64 enrolled
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
Recruiting·Roche logoRoche·N/A·NCT06780150·842 enrolled
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT07224373·24 enrolled
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT04625153·30 enrolled
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Recruiting·AAutolus Limited·Phase 1·NCT07139743·18 enrolled
Vancomycin Study in Multiple Sclerosis (MS)
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT05539729·12 enrolled
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Recruiting·NNorthwestern University·Phase 4·NCT07225361·40 enrolled
AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis
Recruiting·SSt. Petersburg State Pavlov Medical University·Phase 1·NCT05832515·200 enrolled
This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.
Recruiting·WWashington University School of Medicine·N/A·NCT07115017·80 enrolled
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
Recruiting·NNeurology Center of New England P.C.·N/A·NCT06681623·20 enrolled
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
Recruiting·IImStem Biotechnology·Phase 1·NCT04956744·30 enrolled
Page 1 of 52

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)